8.20 Online Preliminary
Clear Guide SCENERGY is Improved Image Fusion: CT/MRI Clarity + Ultrasound Motion. SCENERGY connected to ultrasound equipment with curved probe, showing both live image fusion and targeting guidance.
What SCENERGY can do
- Fuses the motion of ultrasound and the clarity of CT
- Multiple modalities – dynamic or static imagery
- Automatic and continuous registration in under 10 seconds
- Eliminate bulky equipment and magnets
- Instrument guidance without wires, using your instruments
- Tracking and guidance for up to 6 different instruments simultaneously
- Intuitive touchscreen interaction
- Uses your existing ultrasound equipment
- Expands the usage and efficiency of your ultrasound suite (Inquire about availability in your region).
We are developing safe and effective therapeutics for diabetes, obesity and metabolism. Our therapeutics work entirely in the gut where they trigger specific cellular receptors causing the release of therapeutic levels of key metabolic hormones, including GLP-1, PYY, & CCK. Your own hormones work naturally, safely and without side effects to control blood sugar, metabolism, appetite and food intake.
Our patented IP includes a method to restrict our agents to the gut preventing systemic absorption. This method not only eliminates any adverse systemic side effects, but it also enhances and extends the activity of our agents in the gut.
Finally, our identification and selection of completely safe and natural biological compounds that fully trigger these receptors allow us to commercialize our technologies in multiple markets. Our product applications include nutraceuticals, targeted diabetic, diet, medical & functional food products and pharmaceuticals. We have a market-ready prototype.
MIA (Mammography Image Analysis) – Mammography Automated Comparison platform of new and changed breast tissue. A decision support system and Medical Record platform for the Breast Cancer diagnosis and prevention.
MIA’s platform provides accurate and safe breakthrough mass use and safe breast cancer diagnosis ensured by a combination of new AI technology, algorithms and physician’s supervision. The platform supports radiologists to immediately identify changes and digitally enhances the suspected area, highlighting any new or changed breast tissue and any additional parameters defined in the screening images. Using MIA’s computer-aided detection technology during screening mammography for millions of women annually will help improve breast cancer detection.
The SmartTab™ is an ingestible capsule, wireless remote controlled drug delivery system providing effective and targeted drug delivery. An ingestible capsule that is swallowed by the patient and travels through the gastrointestinal tract releasing therapeutics at the right place and at the right time. The SmartTab™ utilizes wireless control, an inductive power (no on-board batteries) and proprietary smart polymer technology for the actuation/release system. The SmartTab capsule technology will integrate with current FDA approved active ingredients following the 505(b)(2) regulatory pathway.
Vivacelle Bio, Inc. is a clinical stage biotechnology company advancing new paradigms in the survival of massive blood loss and severe infection of the blood. The company has developed VBI-1 and VBI-S, formulations comprising injectable phospholipid nanoparticles to sustain life after hypovolemia due to blood loss & sepsis. On Feb. 1, 2019 the US Food and Drug Administration (FDA) granted clearance to initiate our phase IIa clinical trial using VBI-1 to treat hypovolemia (low blood volume) primarily due to hemorrhagic shock (severe rupture of blood vessels) which can lead to a fatal drop in blood pressure. On May 31, 2019, through Dr. Simpkins, our Chief Innovation Officer and Founder who is also a practicing physician, an Investigational New Drug Application was submitted for FDA clearance to begin clinical trials for VBI-S, a variation of VBI-1, that is specifically designed to raise blood pressure (treat hypotension) in septic shock patients. Vivacelle Bio, Inc. provided support for the investigational new drug application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S.
Galen Robotics was founded in 2016 to commercialize the research done in the Laboratory of Computational Sensing and Robotics of Johns Hopkins University. Dr. Kevin Olds and Dr. Russell Taylor invented the Robotic ENT Microsurgical System (REMS) at JHU to prevent the complications caused by hand tremor in minimally invasive otolaryngological interventions.
WEGO HOLDING COMPANY LIMITED (“WEGO”)
Oriza Seed Fund Management
AMERICA P & G CO.